Have questions? Visit https://www.reddit.com/r/SNPedia

rs2257212

From SNPedia

Orientationminus
Stabilizedminus
Geno Mag Summary
(A;A) 2 The A allele ( assumed to be T) responds better to sorafenib in HCC
(A;G) 2 AG as AA responds better to sorafenib during HCC treatment
(G;G) 0 GG genotype responds less well to sorafenib during HCC treatment
ReferenceGRCh38 38.1/141
Chromosome3
Position121924957
GeneSLC15A2
is asnp
is mentioned by
dbSNPrs2257212
ebirs2257212
HLIrs2257212
Exacrs2257212
Varsomers2257212
Maprs2257212
PheGenIrs2257212
hapmaprs2257212
1000 genomesrs2257212
hgdprs2257212
ensemblrs2257212
gopubmedrs2257212
geneviewrs2257212
scholarrs2257212
googlers2257212
pharmgkbrs2257212
gwascentralrs2257212
openSNPrs2257212
23andMers2257212
23andMe allrs2257212
SNP Nexus

SNPshotrs2257212
SNPdbers2257212
MSV3drs2257212
GWAS Ctlgrs2257212
GMAF0.4908
Max Magnitude2
? (A;A) (A;G) (G;G) 28


GET Evidence
SLC15A2-L350F
aa_change Leu350Phe
aa_change_short L350F
impact not reviewed
qualified_impact Insufficiently evaluated not reviewed
overall_frequency 0.467733
summary



A preliminary study found that response to sorafenib in hepatocellular carcinoma was better and resulted in longer progression-free survival time for rs2257212 (C;T) and (T;T) patients than for those with (C;C) genotypes. SLC15A2, the gene harboring rs2257212, is a solute carrier family member that is known to be involved in drug transport. [PMID 25965825OA-icon.png]